Matches in SemOpenAlex for { <https://semopenalex.org/work/W3169186744> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W3169186744 abstract "Abstract Background and Aims The aim of this analysis based on the real-world database was to observe the effect of paricalcitol on the safety profile in Chinese hemodialysis (HD) patients with secondary hyperparathyroidism (SHPT) under routine clinical practice. Method From the Better Life for Future database, a total of 668 Chinese hemodialysis patients from 104 dialysis centers between January 2015 and May 2019 were included in the analysis set. Intact parathyroid hormone (iPTH), total serum calcium (Ca), phosphate (P), dosage of intravenous (IV) paricalcitol (Zemplar®) were analyzed and discussed via retrospective analysis of the database during the treatment. Results Patients were divided into five groups according to the duration of follow-up. Median iPTH levels decreased from 1183 pg/ml at baseline to 676 pg/ml at the final visit, or 30.88% (p < 0.0001). Serum Ca levels shown significantly increased just in the group of Month 12–24 (P=0.0479) (Table 2). The incidence of hypercalcemia for three consecutive blood draws was significantly lower than the incidence of hypercalcemia for at least once or two draws in all groups (Table 3). Subgroup analyses of patients with hyperphosphatemia showed a rapid phosphate reduction, within the first few weeks, along with the reduction in the iPTH level (Figure 1). Conclusion This is the first national retrospective real-world observational study since intravenous paricalcitol is available in China since 2014. This study adds valuable information to real-world data investigating the use of paricalcitol in Chinese HD patients and demonstrated the use of paricalcitol as an effective and well-tolerated treatment for the control of PTH during its use in routine practice. The occurrence of hypercalcemia is mostly transient, followed by continuous treatment, the blood calcium level tends to be stabilized, and the blood phosphorus level will be improved with the control of PTH." @default.
- W3169186744 created "2021-06-22" @default.
- W3169186744 creator A5030478269 @default.
- W3169186744 creator A5052232715 @default.
- W3169186744 date "2021-05-01" @default.
- W3169186744 modified "2023-10-16" @default.
- W3169186744 title "MO806SAFETY OF INTRAVENOUS PARICALCITOL TREATMENT IN CHINESE HEMODIALYSIS PATIENTS: A REAL-WORLD DATABASE ANALYSIS" @default.
- W3169186744 doi "https://doi.org/10.1093/ndt/gfab096.0015" @default.
- W3169186744 hasPublicationYear "2021" @default.
- W3169186744 type Work @default.
- W3169186744 sameAs 3169186744 @default.
- W3169186744 citedByCount "0" @default.
- W3169186744 crossrefType "journal-article" @default.
- W3169186744 hasAuthorship W3169186744A5030478269 @default.
- W3169186744 hasAuthorship W3169186744A5052232715 @default.
- W3169186744 hasConcept C120665830 @default.
- W3169186744 hasConcept C121332964 @default.
- W3169186744 hasConcept C126322002 @default.
- W3169186744 hasConcept C126894567 @default.
- W3169186744 hasConcept C167135981 @default.
- W3169186744 hasConcept C187960798 @default.
- W3169186744 hasConcept C2776036575 @default.
- W3169186744 hasConcept C2778063415 @default.
- W3169186744 hasConcept C2778838027 @default.
- W3169186744 hasConcept C2779524405 @default.
- W3169186744 hasConcept C2779978075 @default.
- W3169186744 hasConcept C2781208988 @default.
- W3169186744 hasConcept C41008148 @default.
- W3169186744 hasConcept C44249647 @default.
- W3169186744 hasConcept C519063684 @default.
- W3169186744 hasConcept C61511704 @default.
- W3169186744 hasConcept C71924100 @default.
- W3169186744 hasConcept C77088390 @default.
- W3169186744 hasConceptScore W3169186744C120665830 @default.
- W3169186744 hasConceptScore W3169186744C121332964 @default.
- W3169186744 hasConceptScore W3169186744C126322002 @default.
- W3169186744 hasConceptScore W3169186744C126894567 @default.
- W3169186744 hasConceptScore W3169186744C167135981 @default.
- W3169186744 hasConceptScore W3169186744C187960798 @default.
- W3169186744 hasConceptScore W3169186744C2776036575 @default.
- W3169186744 hasConceptScore W3169186744C2778063415 @default.
- W3169186744 hasConceptScore W3169186744C2778838027 @default.
- W3169186744 hasConceptScore W3169186744C2779524405 @default.
- W3169186744 hasConceptScore W3169186744C2779978075 @default.
- W3169186744 hasConceptScore W3169186744C2781208988 @default.
- W3169186744 hasConceptScore W3169186744C41008148 @default.
- W3169186744 hasConceptScore W3169186744C44249647 @default.
- W3169186744 hasConceptScore W3169186744C519063684 @default.
- W3169186744 hasConceptScore W3169186744C61511704 @default.
- W3169186744 hasConceptScore W3169186744C71924100 @default.
- W3169186744 hasConceptScore W3169186744C77088390 @default.
- W3169186744 hasLocation W31691867441 @default.
- W3169186744 hasOpenAccess W3169186744 @default.
- W3169186744 hasPrimaryLocation W31691867441 @default.
- W3169186744 hasRelatedWork W12167207 @default.
- W3169186744 hasRelatedWork W13410599 @default.
- W3169186744 hasRelatedWork W15438091 @default.
- W3169186744 hasRelatedWork W15964608 @default.
- W3169186744 hasRelatedWork W17784472 @default.
- W3169186744 hasRelatedWork W18721203 @default.
- W3169186744 hasRelatedWork W20208395 @default.
- W3169186744 hasRelatedWork W5525667 @default.
- W3169186744 hasRelatedWork W8469150 @default.
- W3169186744 hasRelatedWork W195887 @default.
- W3169186744 isParatext "false" @default.
- W3169186744 isRetracted "false" @default.
- W3169186744 magId "3169186744" @default.
- W3169186744 workType "article" @default.